Barriers to utilizing diabetes devices

With the growing number of diabetes devices on the market, including insulin pumps and continuous glucose monitors, patients are taking control of their diabetes. Just how interested patients are and what barriers these devices must overcome to reach patients is unknown. A recent study, published in Diabetes Care, identifies the barriers diabetes devices face and which patients use them.

Even with the amount of technology making managing diabetes more simple and effective, the use of these devices remain low. The study is led by first author, Molly L. Tanenbaum, who aims to identify barriers on device uptake as well as which patients use these devices and the differences in age and sex.

Results from the sample of 1,503 adults with Type 1 diabetes included:

·        47 percent of participants listed the hassle of wearing devices as the biggest barrier

·        35 percent of participants disliked having devices on the body

·        37 percent used continuous glucose monitor

·        Continuous glucose monitoring users were older, had diabetes longer, had a more positive view of technology and reported fewer barriers than non-users.

·        The youngest age group had the lowest uptake of continuous glucose monitors and insulin pumps but also had the highest rates of diabetes distress and blood glucose levels.

“Efforts to increase device use need to target physical barriers to wearing devices,” concluded Tanenbaum and colleagues. “Because young adults had the lowest device uptake rates, highest distress, and highest HbA1c compared with older age-groups, they should be the focus of future interventions to increase device use.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.